Automated Visual Fields
Humphrey Field Analyzer 745i
The Gold Standard
The Humphrey® Field Analyzer II-i (HFA II-i) with new Guided Progression Analysis™ (GPA) software accurately determines the stage of disease, rate of progression and a patient's risk of future vision loss by automatically summarizing all available visual field test results on a single page and by calculating each patient's rate of visual field deterioration. With this advanced perimeter, eye care providers can more closely monitor changes in the eye to prevent irreversible loss of vision for a disease that often has no warning signs and is the second leading cause of blindness worldwide, according to the World Health Organization.
Humphrey Field Analyzers are used by more eye care providers than any other automated diagnostic perimeter today and more than 60 thousand units have been sold since the first system was introduced in 1984. The HFA II-i is the newest and most advanced visual field testing platform and the GPA feature adds significant new diagnostic power to this established platform.
"Vision loss from glaucoma is irreversible. Thus, it is vital that doctors be able to efficiently differentiate between those patients who are doing well on present therapy versus those who are not stabilized, only by identifying the patients who continue to progress can glaucoma be appropriately managed to prevent vision loss or even blindness."
With Guided Progression Analysis software, the HFA II-i's standard printout presents each glaucoma patient's baseline fields, disease staging versus time, rate of progression and most recent test result - all on a single page. This new presentation format is designed to simplify and streamline clinical processes. GPA uses VFI, or Visual Field Index, to correlate with ganglion cell density and is less affected by cataract and other media changes compared with earlier indices. The HFA II-i's GPA program is based upon data gathered from a 15-center international clinical trial and its progression event analysis was used as an endpoint in the Early Manifest Glaucoma Trial.
